Equities analysts expect Sientra Inc (NASDAQ:SIEN) to post ($0.49) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Sientra’s earnings, with estimates ranging from ($0.60) to ($0.42). Sientra posted earnings per share of ($0.72) during the same quarter last year, which suggests a positive year-over-year growth rate of 31.9%. The company is expected to announce its next quarterly earnings report after the market closes on Tuesday, November 5th.
On average, analysts expect that Sientra will report full year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.28) to ($2.66). For the next year, analysts forecast that the company will report earnings of ($1.76) per share, with EPS estimates ranging from ($2.51) to ($1.36). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Sientra.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.50). The company had revenue of $20.53 million for the quarter, compared to analysts’ expectations of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.73) EPS.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Hong Kong Ltd raised its position in shares of Sientra by 282.5% in the second quarter. Point72 Hong Kong Ltd now owns 3,997 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 2,952 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new position in Sientra during the second quarter worth approximately $59,000. Private Advisor Group LLC acquired a new position in Sientra during the second quarter worth approximately $62,000. Bailard Inc. increased its position in Sientra by 28.9% during the second quarter. Bailard Inc. now owns 25,000 shares of the medical instruments supplier’s stock worth $154,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Ardsley Advisory Partners LP acquired a new position in Sientra during the second quarter worth approximately $166,000. 88.91% of the stock is currently owned by institutional investors.
SIEN stock traded down $0.07 during trading on Friday, reaching $6.43. 363,679 shares of the company were exchanged, compared to its average volume of 664,321. The company has a market cap of $320.39 million, a P/E ratio of -1.98 and a beta of 0.24. Sientra has a 52-week low of $4.78 and a 52-week high of $23.32. The stock’s 50 day moving average price is $6.63 and its 200 day moving average price is $6.72. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.99 and a current ratio of 2.33.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.